Skip to main content

Table 1 6-month Progression-free survival and median overall survival for recurrent or metastatic malignant meningioma treated with systemic therapy

From: Grade III meningioma with gastro-intestinal tract and brain metastases: case report and review of the literature

Authors Year Study type Drug used Grade III meningioma (#) 6-month PFS (%) Median OS (month)
Mazza et al. [25] 2016 Phase II, prospective Hydroxyurea 8 NA 27.5
Mazza et al. [25] 2016 Phase II, prospective Hydroxyurea + imatinib 7 NA 6
Kaley et al. [26] 2015 Phase II, prospective Sunitinib 6 44 24.6
Simo et al. [20] 2014 Phase II, prospective Octreotide 4 44 18.7
Raizer et al. [23] 2014 Phase II, prospective Valatanib 8 37.5 23
Lou et al. [21] 2012 Retrospective Bevacizumab 3 87.5 NA
  1. NA Not Available